cognitive cybersecurity intelligence

News and Analysis

Search

A16z’s Vijay Pande Weighs in on M&A Activity, Obesity Drugs, Gene Editing, and AI

Vijay Pande, founding investor of venture capitalist company Andreessen Horowitz’s Bio + Health fund, discusses advances in biopharmaceutical merger and acquisition (M&A) activity, gene editing, and artificial intelligence (AI) applications in life sciences. He suggests AI shows promise in unlocking the complexities of human disease biology, potentially enhancing the success rate of clinical trials and thereby lowering costs and speeding up drug development. Pande also indicates that M&A activity is expected to surge in 2024.

Source: www.genengnews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

Risk Non-Payment or Deny Medications

A ransomware attack by the ‘Blackcat’ group on UnitedHealth Group subsidiary Change Healthcare has disrupted payment systems and prescription processing in nearly 90% of US